Savolitinib

Savolitinib
Clinical data
Other names	Volitinib
Identifiers
	IUPAC name 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine;
CAS Number	1313725-88-0;
ChemSpider	34501055;
UNII	2A2DA6857R;
KEGG	D11139;
ChEBI	CHEBI:231369;
CompTox Dashboard (EPA)	DTXSID801111016 ;
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C17H15N9
Molar mass	345.370 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21;
	InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1; Key:XYDNMOZJKOGZLS-NSHDSACASA-N;

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.^[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.^[2] It has been given conditional approval for these indication in China.^[3]

References

^ "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
^ "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
^ Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538. S2CID 237344020.